Radioembolization for Hepatocellular Carcinoma: A Nationwide 10-year experience
Figure- Use of radioembolization in patients with HCC during the period 2003–2012.
The findings of this study identify some prognostic factors that might influence the overall survival in HCC patients being treated with TARE. In the current environment where HCC can be treated with surgery, transplantation, catheter directed therapies (TAE, TACE, TARE), ablations, and systemic therapy, it is important to identify which patients will benefit the most from TARE therapy. The use of the NCDB database provides strength to this study since a large number of patients are included. Patients had various demographic characteristics, presented either to academic or community hospitals, possessed different types of insurance, belonged to different socioeconomic groups, and presented with different tumor sizes and tumor stages. Therefore this analysis evaluates many variables that are encountered in every day practice. The results in this study highlight that age of presentation is not as important as sex, AJCC stage, tumor size and insurance type. More studies are necessary to identify which HCC patients benefit the most from TARE treatment.
Click here for abstract
Tohme S, Bou Samra P, Kaltenmeier C, Chidi AP, Varley PR, Tsung A. Radioembolization for Hepatocellular Carcinoma: A Nationwide 10-Year Experience. J Vasc Interv Radiol. 2018; 29(7):912-919.
Carlos J. Guevara, MD
Department of Radiology, Interventional Radiology Division
University of Texas Health Sciences, Houston